<DOC>
	<DOCNO>NCT02179489</DOCNO>
	<brief_summary>Multicentric randomise trial . The goal clinical research study learn hyperthermic intraperitoneal chemotherapy ( HIPEC ) help decrease rate peritoneal carcinomatosis ( PC ) patient high risk develop PC colorectal cancer . The safety treatment also study .</brief_summary>
	<brief_title>Trial Evaluating Surgery With Hyperthermic Intraperitoneal Chemotherapy ( HIPEC ) Treating Patients With High Risk Developing Colorectal Peritoneal Carcinomatosis</brief_title>
	<detailed_description>Hyperthermic intraperitoneal chemotherapy ( HIPEC ) recently validate option treatment peritoneal carcinomatosis colorectal ovarian origin . This therapeutic program demonstrate significant improvement overall survival disease . It yet know whether surgery follow HIPEC effective decreasing rate peritoneal carcinomatosis ( PC ) patient high risk develop PC colorectal cancer.Patients high risk develop colorectal Peritoneal Carcinomatosis ( PC ) , define Colorectal Cancer With Resected Minimal Synchronous PC Ovarian Metastases , identify T4 intraoperative pathological diagnosis , Tumour Rupture Abdominal Cavity . If patient high risk develop PC identify preoperative examination , inform sign consent . After complete resection tumor , randomise surveillance alone ( control group ) HIPEC ( experimental group ) . All patient receive current standard postoperative adjuvant treatment : 6 month systemic chemotherapy ( currently include FOLFOX4 , mFOLFOX6 , CapeOx Capecitabine regimen could modify standard modify ) . Then work-up do find recurrence . If recurrence occurs , patient treat best know treatment .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Krukenberg Tumor</mesh_term>
	<criteria>Patients present follow history : 1 . Histologicallyproven colorectal adenocarcinoma 2 . Presenting time resection primary one follow 5 criterion ( criterion indicate high risk develop PC ) : Minimal PC , resect time primary Ovarian metastasis Rupture primary tumour inside peritoneal cavity , Intraoperative rupture primary tumour surgery Histologicallyproven T4 colorectal adenocarcinoma Who receive standard systemic adjuvant chemotherapy ( 6 month systemic chemotherapy ) : 1 . Chemotherapy FOLFOX4 , mFOLFOX6 , CapeOx Capecitabine ( current standard treatment ; modify future two group , standard modify ) 2 . Given intenttotreat basis ( stop prematurely miscellaneous reason ) Patients present sign tumour recurrence end 6 month chemotherapy Patients follow general characteristic : 1 . Age 18 75 year 2 . Performance Status ( ECOG ) 0 , 1 2 , life expectancy &gt; 12 week 3 . Adequate renal , bone marrow function : a. Leukocytes &gt; /= 3,000/microL ; b . Absolute neutrophil count &gt; /= 1,500/microL ; c. Platelets &gt; /= 100,000/Ul ; d. Serum creatinine &lt; /= 1.5 mg/dL 4 . Hepatic function : a. AST ( SGOT ) /ALT ( SGPT ) &lt; /= 5 X institutional ( Upper Limit Normal ) ULN 5 . Operable patient 6 . Completion neoadjuvant systemic chemotherapy Patients inform signed consent initiating procedure specific trial 1 . Cancers non colorectal origin 2 . Patients present detectable recurrent tumour 3 . History cancer ( except cutaneous basal cell carcinoma situ carcinoma uterine cervix ) recurrence 5 previous year 4 . Known HIV , Hepatitis B Hepatitis C positive 5 . Pregnant woman likely pregnant 6 . Persons guardianship 7 . Subjects deem unable comply study and/or followup procedure . 8 . Subjects know hypersensitivity protocol systemic chemotherapy lifethreatening , require hospitalization prolongation exist hospitalization , result persistent significant disability incapacity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Peritoneal carcinomatosis</keyword>
	<keyword>HIPEC</keyword>
	<keyword>control clinical trial</keyword>
	<keyword>colorectal cancer</keyword>
</DOC>